Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
Evelo Biosciences (Nasdaq:EVLO) reported key updates from its Phase 1b trial of EDP1815, demonstrating significant efficacy in treating atopic dermatitis. The company strengthened its leadership team, appointing Luca Scavo as CFO and Julie H. McHugh to the Board. A strategic collaboration with Abdul Latif Jameel Health was announced to commercialize EDP1815 in select developing markets. Financially, Evelo showed a cash position of $124.6 million but reported a net loss of $28.2 million for Q1 2021, widening from the previous year. Management anticipates multiple clinical readouts over the next 18 months.
- EDP1815 trial showed significant improvement in IGA scores, outperforming placebo by 31%.
- Strategic collaboration with Abdul Latif Jameel Health expands market reach in the Middle East, Turkey, and Africa.
- Cash reserves increased to $124.6 million, up from $68.9 million at year-end 2020.
- Net loss increased to $28.2 million in Q1 2021, up from $23 million in Q1 2020.
- Delayed COVID-19 trial results due to lower patient enrollment amid increased vaccination rates.
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting–
–Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors–
–Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets–
–Multiple clinical data readouts expected over next 18 months–
–Management to host conference call at 8:30 a.m. ET–
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the first quarter 2021.
“Over the past year, we have executed on our research and development plans, providing critical preclinical and clinical data to help inform our late-stage development plans, and further validating our platform. We are poised to continue building on this momentum, with multiple clinical readouts expected across our inflammatory disease portfolio in the next 18 months, including our Phase 2b data from EDP1815 in psoriasis in the third quarter,” said Simba Gill, Ph.D., Chief Executive Officer of Evelo. “In order to support this rapid growth, we continue to strengthen our corporate position. We recently expanded our executive team with the addition of Luca Scavo as CFO and Julie H. McHugh to our Board of Directors, and entered into a strategic collaboration with Abdul Latif Jameel Health to potentially provide EDP1815 to the Middle East, Turkey, and Africa, representing a key step in realizing our vision of providing safe, effective, convenient, and affordable medicines to millions of people around the world.”
First Quarter 2021 Highlights and Recent Progress
EDP1815 in Atopic Dermatitis
- In April 2021, Evelo presented full clinical data from the Phase 1b clinical trial cohort evaluating EDP1815 for the treatment of mild and moderate atopic dermatitis in a poster presentation at the International Society of Atopic Dermatitis (ISAD) Hybrid Meeting 2021. The Company previously reported positive data for all 24 patients in the cohort, which is re-iterated in the presentation, together with new data on the Investigator Global Assessment (IGA) score.
- The full results reinforce the data released in January 2021, demonstrating that treatment with EDP1815 resulted in clinically meaningful improvements in both patient- and physician-reported outcomes.
- At the day 70 follow-up visit,
31% more EDP1815-treated patients achieved an IGA score of 0 or 1 greater than placebo. At this same time-point,19% more EDP1815-treated patients reached an IGA score of 0 or 1 with a two-point improvement from baseline greater than placebo. - These data, in addition to the treatment differences seen within the Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), and IGA times Body Surface Area (IGA*BSA) clinical endpoints, suggest the potential of EDP1815 to be a safe, effective, well-tolerated, oral treatment for patients with mild and moderate atopic dermatitis.
- As previously disclosed, EDP1815 was well tolerated, with no treatment-related adverse events of moderate or severe intensity and no serious adverse events.
EDP1815 TACTIC-E Trial in COVID-19
- The planned review of interim data after the first 90 patients enrolled in the trial (including 30 patients treated with EDP1815) was conducted by the Independent Data Monitoring Committee in accordance with the protocol. No safety issues for EDP1815 were identified. The trial has therefore proceeded with continued recruitment. The next review of safety and efficacy data will be after approximately 125 patients have been enrolled into the EDP1815 arm of the trial.
Business Highlights
- In March 2021, Evelo announced a strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in the Middle East, Turkey, and Africa. The collaboration leverages Evelo’s leadership in inflammatory diseases and Abdul Latif Jameel’s regional distribution expertise, with the goal of accelerating the delivery of EDP1815 as an effective, affordable medicine to people in select developing markets, many of whom suffer significant challenges in accessing medical care. Under the terms of the agreement, Evelo received an upfront payment and equity investment. Evelo will be responsible for the development and manufacturing of EDP1815, whilst Abdul Latif Jameel Health will be responsible for regulatory submissions and commercialization activities in the agreed-upon regions. Evelo and Abdul Latif Jameel Health will participate in a 50:50 profit share arrangement.
- In April 2021, Evelo announced the appointments of Luca Scavo as Chief Financial Officer and a member of the Evelo Leadership Team, effective June 1, 2021, and Julie H. McHugh to the Board of Directors, effective immediately.
Upcoming Key Milestones
EDP1815 – Psoriasis; all data anticipated to be reported in 3Q 2021
- Data from Phase 1b cohorts with tablets and capsules
- Full data from Phase 2b dose-ranging trial
EDP1815 – Atopic Dermatitis
- Subject to regulatory approval, initiation of Phase 2 trial in 3Q 2021
EDP1815 – COVID-19
- While patient accrual for both COVID-19 trials continued during the quarter, given the increase in vaccination rates, and lower number of patients hospitalized with COVID-19 at clinical trial sites, Evelo expects the trials will continue longer than originally planned. The Company is unsure when it will be able to report data, and therefore will no longer be issuing guidance related to these trials.
EDP1867 – Atopic Dermatitis
- Interim data from Phase 1b trial expected in 4Q 2021
EDP2939 – Inflammation
- Initiation of clinical development in 2022
EDP1908 – Oncology
- Initiation of clinical development in 2022
First Quarter 2021 Financial Results
- Cash Position: As of March 31, 2021, cash and cash equivalents were
$124.6 million , as compared to cash and cash equivalents of$68.9 million as of December 31, 2020. This increase was primarily due to net proceeds of$82.0 million received from the Company’s issuance of common stock, partially offset by cash used to fund operating activities and capital expenditures in the first quarter of 2021. - Research and Development Expenses: R&D expenses were
$21.5 million for the three months ended March 31, 2021, compared to$17.4 million for the three months ended March 31, 2020. The increase of$4.1 million was primarily due to increased costs related to Evelo’s inflammation clinical development programs and personnel costs, partially offset by decrease in R&D platform and oncology programs. - General and Administrative Expenses: G&A expenses were
$6.0 million for the three months ended March 31, 2021, compared to$5.8 million for the three months ended March 31, 2020. The increase of$0.1 million was primarily due to increased personnel costs and other costs. - Net Loss: Net loss was
$28.2 million for the three months ended March 31, 2021, or$(0.55) per basic and diluted share, as compared to a net loss of$23.0 million for the three months ended March 31, 2020, or$(0.71) per basic and diluted share.
Conference Call
Evelo will host a conference call and webcast at 8:30 a.m. ET today. To access the call please dial (866) 795-3242 (domestic) or (409) 937-8909 (international) and refer to conference ID 5856668. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the
potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements concerning the development of EDP1815, EDP1867, EDP2939, and EDP1908, the promise and potential impact of our product candidates, the timing of and plans for clinical trials, and the timing and results of clinical trial readouts.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our reliance on third parties and collaborators to expand our microbial library, conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; our lack of experience in manufacturing, selling, marketing, and distributing our product candidates; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; our management and principal stockholders have the ability to control or significantly influence our business; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us.
These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the three months ended March 31, 2021 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Contact
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
EVELO BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||||||||
| 2021 | 2020 | |||||||
| Operating Expenses (1): | ||||||||
| Research and development | $ | 21,508 | $ | 17,419 | ||||
| General and administrative | 5,963 | 5,842 | ||||||
| Total operating expenses | 27,471 | 23,261 | ||||||
| Loss from operations | (27,471 | ) | (23,261 | ) | ||||
| Other (expense) income, net | (603 | ) | 285 | |||||
| Loss before income taxes | (28,074 | ) | (22,976 | ) | ||||
| Income tax expense | (122 | ) | (65 | ) | ||||
| Net loss | $ | (28,196 | ) | $ | (23,041 | ) | ||
| Net loss per share - basic and diluted | $ | (0.55 | ) | $ | (0.71 | ) | ||
| Weighted-average common shares used in computing net loss per share - basic and diluted | 51,343,923 | 32,250,050 | ||||||
| (1) Expenses include the following amount of non-cash stock-based compensation expense. | ||||||||
| General and administrative | $ | 1,441 | $ | 889 | ||||
| Research and development | 1,823 | 1,066 | ||||||
EVELO BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands)
| March 31, 2021 | December 31, 2020 | |||||||
| Assets: | ||||||||
| Cash and cash equivalents | $ | 124,591 | $ | 68,857 | ||||
| Property and equipment, net | 7,236 | 7,478 | ||||||
| Right of use asset - operating lease | 10,312 | 10,757 | ||||||
| Other assets | 10,903 | 3,547 | ||||||
| Total assets | $ | 153,042 | $ | 90,639 | ||||
| Liabilities and stockholders’ equity: | ||||||||
| Accounts payable, accrued expenses and other | $ | 18,719 | $ | 19,833 | ||||
| Long-term debt | 29,258 | 30,048 | ||||||
| Operating lease liability, net of current portion | 9,463 | 9,989 | ||||||
| Other noncurrent liabilities | 7,763 | 284 | ||||||
| Total liabilities | 65,203 | 60,154 | ||||||
| Total stockholders’ equity | 87,839 | 30,485 | ||||||
| Total liabilities and stockholders’ equity | $ | 153,042 | $ | 90,639 | ||||
FAQ
What are the latest results from Evelo Biosciences' EDP1815 trial as of April 2021?
Who were the new appointments in Evelo's leadership team announced in April 2021?
What financial position did Evelo report for Q1 2021?
What is the significance of the collaboration with Abdul Latif Jameel Health for Evelo?
What clinical data readouts can we expect from Evelo in the upcoming months?
